Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence dependence and platinum content.

abstract：:In the present study we investigated the enhancement of cytotoxicity of peritoneal macrophages induced by OK-432. Rats received an i.p. injection of OK-432 at doses of 0.1, 0.5 or 1.0 KE/rat. Two days later, rats were sacrificed and peritoneal macrophages were isolated. Then the number of macrophages was counted, and ...

journal_title：Anti-cancer drugs

authors： Huang Y,Xu Y,Yamagishi H,Hagiwara A

更新日期：2001-10-01 00:00:00

abstract：:In this study the activity of KW-2149 and two of its metabolites, M-16 and M-18, was measured against cell lines with different types of resistance. The influence of these metabolites and of the exposure time on the cytotoxic efficacy of KW-2149 was investigated. Against the human ovarian carcinoma cell lines, AOvC an...

journal_title：Anti-cancer drugs

authors： Dirix LY,Gheuens EE,van der Heyden S,van Oosterom AT,De Bruijn EA

更新日期：1994-06-01 00:00:00

abstract：:Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has ...

journal_title：Anti-cancer drugs

authors： Shu S,Yamashita-Kashima Y,Yanagisawa M,Nakanishi H,Kodera Y,Harada N,Yoshimura Y

更新日期：2020-03-01 00:00:00

abstract：:Lymphocytes regenerated after treatment with a high dose of cyclophosphamide (CY) were characterized in nude mice. Ten days after a single injection of 200 mg/kg CY into nude mice, regenerated spleen cells suppressed in vitro primary and second antibody production against sheep red blood cells. The CY-treated spleen c...

journal_title：Anti-cancer drugs

authors： Shimizu M,Sabolovic D,Ozawa H,Iwaguchi T

更新日期：1992-08-01 00:00:00

abstract：:This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma. The regimen, composed of paclitaxel 35 mg/m 1-h intravenous infusion on days 1, 4, 8 and 11; c...

journal_title：Anti-cancer drugs

authors： Lin CC,Yeh KH,Yang CH,Hsu C,Tsai YC,Hsu WL,Cheng AL,Hsu CH

更新日期：2007-07-01 00:00:00

abstract：:Esophageal cancer is one of the fatal cancers around the world. Dexmedetomidine (DEX) is widely used during anesthesia of esophageal cancer surgery. Nevertheless, the role of DEX in the progression of esophageal cancer remains barely known. The proliferation, apoptosis and metastasis of esophageal cancer cells were de...

journal_title：Anti-cancer drugs

authors： Zhang P,He H,Bai Y,Liu W,Huang L

更新日期：2020-08-01 00:00:00

abstract：:A new dosage format, cisplatin microcrystals suspended in oil (CDDP-oil), was developed for the treatment of peritoneal carcinomatoses. We studied the acute toxicity of CDDP-oil injected intraperitoneally in mice. The 50% lethal dose was 30.3 mg/kg (27.1-33.7 mg/kg at the 95% confidence level), which was 1.79 times th...

journal_title：Anti-cancer drugs

authors： Tsujimoto H,Hagiwara A,Sakakura C,Sasaki S,Osaki K,Ohyama T,Sakakibara T,Takahashi T

更新日期：1993-06-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial...

journal_title：Anti-cancer drugs

authors： West CM,Price P

更新日期：2004-03-01 00:00:00

abstract：:Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid...

journal_title：Anti-cancer drugs

authors： Pouessel D,Culine S

更新日期：2012-01-01 00:00:00

abstract：:In a retrospective study, we calculated the treatment and follow-up costs of patients with newly diagnosed multiple myeloma. The total treatment programme consisted of eight phases: VAD or VAMP chemotherapy, follow-up I, high-dose melphalan followed by transplantation of whole blood, follow-up II, collection of periph...

journal_title：Anti-cancer drugs

authors： Buijt I,Ossenkoppele GJ,Uyl-de Groot CA,Huijgens PC

更新日期：1998-11-01 00:00:00

abstract：:The recombinant monoclonal antibody trastuzumab has antiproliferative effect on breast cancer (BC) cells with ErbB2 overexpression. We postulated that a mechanism able to modify ErbB2 expression enhances the antitumor effect of trastuzumab. We analyzed whether granulocyte-colony stimulating factor (G-CSF), widely used...

journal_title：Anti-cancer drugs

authors： Cavalloni G,Sarotto I,Pignochino Y,Gammaitoni L,Migliardi G,Sgro L,Piacibello W,Risio M,Aglietta M,Leone F

更新日期：2008-08-01 00:00:00

abstract：:Venetoclax is a first-in-class orally available, B-cell lymphoma (BCL)-2 inhibitor indicated for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. We used a novel approach for evaluating venetoclax pharmacokinetics using only sparse sampling in 155 patien...

journal_title：Anti-cancer drugs

authors： Salem AH,Dunbar M,Agarwal SK

更新日期：2017-09-01 00:00:00

abstract：:Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

journal_title：Anti-cancer drugs

authors： Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

更新日期：2006-06-01 00:00:00

abstract：:To devise a meaningful nutritional therapy in cancer, a greater understanding of nutritional dimensions as well as of expectations of patients and disease impact is essential. We have shown that nutritional deterioration in patients with gastrointestinal and head and neck cancer was multifactorial and mainly determine...

journal_title：Anti-cancer drugs

authors： Ravasco P

更新日期：2011-08-01 00:00:00

abstract：:Taxotere (RP 56976, NSC 628503) is a new semisynthetic analog of taxol (NSC 125973) with promising antitumor activity in a variety of preclinical screening systems. Clinical responses after treatment with taxol have been observed in ovarian cancer, breast, lung cancer and melanoma. Both agents act through induction of...

journal_title：Anti-cancer drugs

authors： Hanauske AR,Degen D,Hilsenbeck SG,Bissery MC,Von Hoff DD

更新日期：1992-04-01 00:00:00

abstract：:A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma. ...

journal_title：Anti-cancer drugs

authors： Rose PG,Roma A

更新日期：2013-10-01 00:00:00

abstract：:The delivery formulation 5-FU-MS [5-fluorouracil (5-FU) incorporated in microspheres composed of a poly(glycolide-co-lactide) matrix] slowly releases 5-FU over 3 weeks. 5-FU-MS delivers higher concentrations of the drug to the i.p. tissues for a longer period of time with lower blood plasma concentrations than does an...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Shirasu M,Yamasaki J,Togawa T,Takahashi T,Muranishi S,Hyon S,Ikada Y

更新日期：1998-03-01 00:00:00

abstract：:Prostaglandin E2 (PGE2) has been shown to play an important role in tumor development and progression. PGE2 mediates its biological activity by binding any one of four prostanoid receptors (EP1 through EP4). The present study was designed to determine the role of the EP2 receptor during the proliferation and apoptosis...

journal_title：Anti-cancer drugs

authors： Hu S,Sun W,Wei W,Wang D,Jin J,Wu J,Chen J,Wu H,Wang Q

更新日期：2013-02-01 00:00:00

abstract：:Tolerability and response rate to weekly combination chemotherapy with trastuzumab and vinorelbine in Japanese women with HER2-overexpressing breast cancer not previously receiving either therapy were assessed. Tumor response was evaluated every 4 weeks and adverse events were graded. A total of 23 patients from six p...

journal_title：Anti-cancer drugs

authors： Tokudome N,Ito Y,Hatake K,Toi M,Sano M,Iwata H,Sato Y,Saeki T,Aogi K,Takashima S

更新日期：2008-08-01 00:00:00

abstract：:Multi-targeted antifolate (MTA) is an anti-metabolite with useful activity in the treatment of non-operable patients presenting with non-small cell lung cancer. Its good efficacy and tolerability profile as first-line therapy was demonstrated in phase II studies of MTA as monotherapy. The use of MTA as second-line the...

journal_title：Anti-cancer drugs

authors： Le Chevallier T

更新日期：2001-07-01 00:00:00

abstract：:This multi-center trial was carried out to assess the therapeutic potential of recombinant tumor necrosis factor (rTNF) as the first form of systemic therapy for advanced carcinomas of gastric and pancreatic origin. To be eligible patients were required to have no overt sign of coagulopathy and hepatic function studie...

journal_title：Anti-cancer drugs

authors： Muggia FM,Brown TD,Goodman PJ,Macdonald JS,Hersh EM,Fleming TR,Leichman L

更新日期：1992-06-01 00:00:00

abstract：:9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

journal_title：Anti-cancer drugs

authors： Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

更新日期：1998-01-01 00:00:00

abstract：:Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

journal_title：Anti-cancer drugs

authors： Ma W,Liu X,Du W

更新日期：2019-02-01 00:00:00

abstract：:Chemotherapy is the only option of treatment for most patients presenting with a recurrent and/or metastatic head and neck squamous cell carcinoma. The triple association of cisplatin, 5-fluorouracile, and cetuximab is still the current standard for fit patients. Other schemes are currently being compared with this pr...

journal_title：Anti-cancer drugs

authors： Karabajakian A,Toussaint P,Neidhardt EM,Paulus V,Saintigny P,Fayette J

更新日期：2017-04-01 00:00:00

abstract：:High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer has been associated with a poor prognosis, indicating that VEGF could be linked to the efficacy of chemotherapy and radiotherapy. It has also been suggested that radiation resistance is partly due to tumour cell production of a...

journal_title：Anti-cancer drugs

authors： Heravi M,Tomic N,Liang L,Devic S,Holmes J,Deblois F,Radzioch D,Muanza T

更新日期：2012-06-01 00:00:00

abstract：:The efficacy of trastuzumab beyond metastatic disease progression (PD) is controversial. We retrospectively analyzed 213 patients with HER2-positive metastatic breast cancer treated with trastuzumab-based therapies between November 1998 and December 2010. Out of 213 patients, 134 (58%) had received trastuzumab consecu...

journal_title：Anti-cancer drugs

authors： Esposito A,Munzone E,Bagnardi V,Adamoli L,Sciandivasci A,Cullurà D,Goldhirsch A,Nolè F

更新日期：2012-11-01 00:00:00

abstract：:Numerous reports on colon carcinogenesis reveal gender differences in the incidence and location of tumors. A large number of the presented studies suggest that sex-steroids have a considerable effect on tumorigenesis of the large bowel. To clarify the, so far, not fully understood mechanisms and somewhat conflicting ...

journal_title：Anti-cancer drugs

authors： Dornschneider G,Izbicki JR,Wilker DK,Schweiberer L

更新日期：1990-10-01 00:00:00

abstract：:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC wer...

journal_title：Anti-cancer drugs

authors： Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

更新日期：2016-11-01 00:00:00

abstract：:The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with ...

journal_title：Anti-cancer drugs

authors： Schmid P,Krocker J,Schulz CO,Michniewicz K,Dieing A,Eggemann H,Heilmann V,Blohmer JU,Sezer O,Elling D,Possinger K

更新日期：2005-01-01 00:00:00

abstract：:Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

journal_title：Anti-cancer drugs

authors： Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

更新日期：2011-07-01 00:00:00